Chiara Salvetti

Real‐World Determinants of Treatment Selection in Frontline Chronic Lymphocytic Leukemia: The FIRST‐CLL Study

Francesca Perutelli, Matteo Arata, Raffaella Pasquale, Sara Pepe et autres

Multiple targeted agents are available for first-line treatment of chronic lymphocytic leukemia (CLL), yet the absence of mature head-to-head comparisons makes treatment selection challenging. The prospective, multicenter FIRST-CLL study evaluated real-world treatment allocation, and the contribution of biological, clinical, logistical and patient-related …

it (code pays fourni par la source)

Unexpected chronic lymphocytic leukemia B cell activation by bisphosphonates

Andrea Nicola Mazzarello, Elena Gugiatti, Vanessa Cossu, Nadia Bertola et autres

Chronic lymphocytic leukemia (CLL) is a disease of the elderly, often presenting comorbidities like osteoporosis and requiring, in a relevant proportion of cases, treatment with bisphosphonates (BPs). This class of drugs was shown in preclinical investigations to also possess anticancer properties. We …

it (code pays fourni par la source)

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated with Expansion and Maturation of NK Cells

Fabio Guolo, Paola Minetto, Silvia Pesce, Filippo Ballerini et autres

ABSTRACT Background. Hodgkin Lymphoma (HL) Hodgkin Lymphoma (HL) is a B-Cell neoplasia characterized by a high degree of response to chemotherapy and an overall favourable outcome in responding patients. Despite the efficacy of first line therapy, however, about 30% of patients affected …

it (code pays fourni par la source)

Case Report: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights

Chiara Salvetti, Candida Vitale, Valentina Griggio, Daniela Drandi et autres

Two main variants of Richter syndrome (RS) are recognized, namely, the diffuse large B-cell lymphoma (DLBCL) and the Hodgkin’s lymphoma (HL) variant. Clonal relationship, defined as an identity of the immunoglobulin heavy chain variable (IGHV) region sequence between chronic lymphocytic leukemia (CLL) …

it, de (code pays fourni par la source)

Clonal haematopoiesis as a risk factor for therapy‐related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo‐(immuno)therapy

Maria Teresa Voso, Tatjana Pandzic, Giulia Falconi, Marija Denčić‐Fekete et autres

Clonal haematopoiesis of indeterminate potential (CHIP) may predispose for the development of therapy-related myeloid neoplasms (t-MN). Using target next-generation sequencing (t-NGS) panels and digital droplet polymerase chain reactions (ddPCR), we studied the myeloid gene mutation profiles of patients with chronic lymphocytic leukaemia …

it, se, rs, gr, cz, by (code pays fourni par la source)

Targeting HIF-1α Regulatory Pathways as a Strategy to Hamper Tumor-Microenvironment Interactions in CLL

Candida Vitale, Valentina Griggio, Chiara Riganti, Maria Chiara Todaro et autres

The hypoxia-inducible factor 1 (HIF-1) and the CXCL12/CXCR4 axis regulate the interaction of chronic lymphocytic leukemia cells and the tumor microenvironment. However, the interconnections occurring between HIF-1 and the CXCL12/CXCR4 axis are not fully elucidated. Here, we demonstrate that the CXCL12/CXCR4 axis …

it (code pays fourni par la source)

Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs

Candida Vitale, Chiara Salvetti, Valentina Griggio, Marika Porrazzo et autres

Autoimmune cytopenias (AICs) affect 5% to 9% of patients with chronic lymphocytic leukemia (CLL). Targeted drugs-ibrutinib, idelalisib, and venetoclax-have a prominent role in the treatment of CLL, but their impact on CLL-associated AICs is largely unknown. In this study, we evaluated the …

it (code pays fourni par la source)

Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia

Valentina Griggio, Francesca Perutelli, Chiara Salvetti, Elia Boccellato et autres

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by a wide range of tumor-induced alterations, which affect both the innate and adaptive arms of the immune response, and accumulate during disease progression. In recent years, the development of targeted therapies, such …

it (code pays fourni par la source)

Clonal Hematopoiesis Is Associated with Increased Risk for Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia Patients Treated with Chemo(immuno)Therapy

Maria Teresa Voso, Tatjana Pandzic, Michail Iskas, Marija Denčić‐Fekete et autres

Clonal haematopoiesis of indeterminate potential (CHIP) is defined by the detection of somatic mutations in genes recurrently mutated in myeloid neoplasms (MNs), in the blood of healthy individuals with normal blood values and lack of morphological evidence of MN. Recent studies have …

it, se, gr (code pays fourni par la source)

CLL-220: Modulation of Phenotypic and Functional Features of Immune Cells in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib

Francesca Perutelli, Valentina Griggio, Candida Vitale, Francesca Romana Mauro et autres

it, ua (code pays fourni par la source)

CLL-131: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights

Chiara Salvetti, Candida Vitale, Valentina Griggio, Daniela Drandi et autres

it, de (code pays fourni par la source)

Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation

Lucia Farina, Francesco Barretta, Lydia Scarfò, Benedetto Bruno et autres

Refractory/early relapsed and 17p deletion/p53 mutation (del(17p)/TP53mut)-positive chronic lymphocytic leukemia (CLL) has been conventionally considered a high-risk disease, potentially eligible for treatment with allogeneic stem cell transplantation (alloSCT). In this multicenter retrospective analysis of 157 patients, we compared the outcomes of patients …

it (code pays fourni par la source)